Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 3, Issue 8, pp. 936-945
PubMed
Published By
Print ISSN
Online ISSN
History
- Received February 24, 2015
- Revision received April 6, 2015
- Accepted April 20, 2015
- Published first May 13, 2015.
Article Versions
- Previous version (May 13, 2015 - 11:23).
- Previous version (July 9, 2015 - 06:04).
- You are viewing the most recent version of this article.
Copyright & Usage
©2015 American Association for Cancer Research.
Author Information
- Raghvendra M. Srivastava1,
- Sumita Trivedi1,
- Fernando Concha-Benavente2,
- Jie Hyun-bae1,
- Lin Wang1,
- Raja R. Seethala3,
- Barton F. Branstetter IV4,
- Soldano Ferrone5, and
- Robert L. Ferris1,2,6,*
- 1Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania.
- 2Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
- 3Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
- 4Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
- 5Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- 6Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
- ↵*Corresponding Author:
Robert L. Ferris, University of Pittsburgh, Hillman Cancer Center Research Pavilion, 5117 Centre Avenue, Room 2.26b, Pittsburgh, PA 15213. Phone: 412-623-0327; Fax: 412-623-4840; E-mail: ferrisrl{at}upmc.edu
August 2015
Volume 3, Issue 8
Volume 3, Issue 8
STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients
Jump to section
Advertisement